The latest Global Initiative for Asthma (GINA) 2025 update also recommends dupilumab, which blocks IL-4/IL-13 signaling via IL-4Rα, and tezepelumab, which targets the upstream epithelial cytokine thymic stromal lymphopoietin (TSLP), expanding treatment options for both T2-high and non–T2 asthma phenotypes (13). This evidence concerns the gene IL4 and asthma.